-

Veracyte to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences.

  • Raymond James 46th Annual Institutional Investors Conference – Orlando, FL
    Presentation on March 5th at 9:50 a.m. Eastern Time
  • Leerink Partners Global Healthcare Conference – Miami, FL
    Fireside Chat on March 11th at 8:40 a.m. Eastern Time

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days after each live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

Contacts

Investors:
Shayla Gorman
investors@veracyte.com
(619) 393-1545

Media:
Tracy Morris
media@veracyte.com
(650) 380-4413

Veracyte, Inc.

NASDAQ:VCYT

Release Versions

Contacts

Investors:
Shayla Gorman
investors@veracyte.com
(619) 393-1545

Media:
Tracy Morris
media@veracyte.com
(650) 380-4413

More News From Veracyte, Inc.

New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer....

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces 8 Abstracts Highlighting Performance and Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25...

Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2024. “I’m incredibly proud of what our team accomplished in 2024,” said Marc Stapley, Veracyte’s chief executive officer. “We ended the year with exceptional performance, delivering record revenue in Q4 and achieving our 10th consecutive quarter of 20% or greater testing revenue growth. Looking ahead to 2025, we see significant op...
Back to Newsroom